Recruiting

Trial ID IM027-1015 | NCT06025578

A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis

About This Trial
Key Eligibility Criteria
Trial Site Locations

Summary

Phase 3
21+

Age Range
252

Locations
Recruiting

Overview

The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis.

Nearest Recruiting Site

Key Eligibility Criteria

Inclusion Criteria

Diagnosis of interstitial lung disease (ILD) with features consistent with progressive ILD within 24 months prior to screening, and ≥ 10% extent of fibrosis on screening high-resolution computed tomography (HRCT).
If on pirfenidone or nintedanib, participants must have been on a stable dose for at least 90 days prior to screening.
If not currently on pirfenidone or nintedanib, participants must not have received either of these medications within 28 days prior to screening.
Mycophenolate mofetil (MMF), mycophenolic acid (MA), azathioprine (AZA), and Tacrolimus are permitted provided that the participant is on a stable dose for at least 90 days prior to screening. If not currently on MMF, MA, AZA, or tacrolimus, participants must not have taken these medications within 28 days prior to screening.
Traditional disease-modifying antirheumatic drug (DMARDs) (eg. Methotrexate, leflunomide, sulfasalazine, or hydroxychloroquine) are permitted provided that the participant is on a stable dose for at least 90 days prior to screening. If not currently on traditional DMARD, participants must not have taken these medications within 28 days prior to screening.
Biologic DMARDs (eg. TNF blockers and IL-1 inhibitors) and Janus kinase inhibitors (JAK inhibitors eg. tofacitinib, upadacitinib) are permitted provided that the participant is on a stable dose for at least 90 days prior to screening. If not currently on Biologic DMARD or JAK inhibitor, participants must not have taken these medications within 28 days prior to screening.
Women who are of childbearing potential must have a highly effective form of contraception and must provide a negative urine/serum pregnancy test.
Men who are sexually active with women of childbearing potential agree to use male barrier contraception.

Exclusion Criteria

Idiopathic pulmonary fibrosis with usual interstitial pneumonia (UIP) verification at screening.
History of stroke or transient ischemic attack within 3 months prior to screening.
Participants who exhibit symptoms of heart failure at rest.
Participants who have a current malignancy or a previous malignancy in the past 5 years prior to screening, except for those who have a documented history of cured nonmetastatic squamous cell skin carcinoma, basal cell skin carcinoma, or cervical carcinoma in situ.
Use of systemic corticosteroids equivalent to prednisone > 15 mg/day is not allowed within 4 weeks prior to screening and during the study.

Additional Information *

Other protocol-defined Inclusion/Exclusion criteria apply.

Treatment Options

Study Arms

ASSIGNED INTERVENTION

Study Arms

Experimental: BMS-986278 Dose 1

ASSIGNED INTERVENTION

Drug: BMS-986278

Study Arms

Experimental: BMS-986278 Dose 2

ASSIGNED INTERVENTION

Drug: BMS-986278

Study Arms

Placebo Comparator: BMS-986278 Placebo

ASSIGNED INTERVENTION

Drug: BMS-986278 Placebo

Take the first step to see if you Match to a Clinical Trial – Check Your Eligibility

Check Your Eligibility

Answer some questions about Your health to see if you may match to this trial

Match to a Trial

If you are a match, click on the study to see the list of study site locations

Select a Study Site Location

Select a study site location that is convenient for you

Provide your contact details for the study site to connect with you.